NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

NCT05046613

RecruitingN/A

Sponsor: Pfizer

Conditions: Migraine

Interventions: Rimegepant, Not taking Rimegepant

Countries: United States

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Eligibility overview

Sex: FEMALE

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
* Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy

Exclusion Criteria:

• Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy

Locations (1)

Wilmington, North Carolina, United States